Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

Abstract Drug combinations are key to circumvent resistance mechanisms compromising response to single anti-cancer targeted therapies. The implementation of combinatorial approaches involving MEK1/2 or KRASG12C inhibitors in the context of KRAS-mutated lung cancers focuses fundamentally on targeting...

書誌詳細
出版年:	Nature Communications
主要な著者:	Irati Macaya, Marta Roman, Connor Welch, Rodrigo Entrialgo-Cadierno, Marina Salmon, Alba Santos, Iker Feliu, Joanna Kovalski, Ines Lopez, Maria Rodriguez-Remirez, Sara Palomino-Echeverria, Shane M. Lonfgren, Macarena Ferrero, Silvia Calabuig, Iziar A. Ludwig, David Lara-Astiaso, Eloisa Jantus-Lewintre, Elizabeth Guruceaga, Shruthi Narayanan, Mariano Ponz-Sarvise, Antonio Pineda-Lucena, Fernando Lecanda, Davide Ruggero, Purvesh Khatri, Enrique Santamaria, Joaquin Fernandez-Irigoyen, Irene Ferrer, Luis Paz-Ares, Matthias Drosten, Mariano Barbacid, Ignacio Gil-Bazo, Silve Vicent
フォーマット:	論文
言語:	英語
出版事項:	Nature Portfolio 2023-10-01
オンライン･アクセス:	https://doi.org/10.1038/s41467-023-41828-z

類似資料

PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?
著者:: Shruthi Narayanan, 等
出版事項: (2021-12-01)

KRAS inhibitors: going noncovalent
著者:: Matthias Drosten, 等
出版事項: (2022-12-01)

Correction: The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
著者:: Rodrigo Entrialgo‑Cadierno, 等
出版事項: (2023-06-01)

The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer
著者:: Rodrigo Entrialgo-Cadierno, 等
出版事項: (2023-05-01)

A Rare Case of Midostaurin-Associated Sweet’s Syndrome
著者:: Hesham Yasin, 等
出版事項: (2022-01-01)

Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
著者:: Ali Chour, 等
出版事項: (2024-09-01)

Tumor Organoids Grown in Mixed-Composition Hydrogels Recapitulate the Plasticity of Pancreatic Cancers
著者:: Ioritz Sorzabal-Bellido, 等
出版事項: (2025-07-01)

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
著者:: Ning Ji, 等
出版事項: (2019-06-01)

Assessment of KRASG12C inhibitors for colorectal cancer
著者:: Gary A. Piazza, 等
出版事項: (2024-06-01)

The KRASG12C inhibitors in lung cancer therapy
著者:: Maciej Jędrak, 等
出版事項: (2023-09-01)

MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis
著者:: Chungui Xu, 等
出版事項: (2024-11-01)

Efficacy and Safety of KRASG12C Inhibitors in Advanced Solid Tumors with KRASG12C-mutated: A Single-arm Meta-analysis
著者:: TAN Dengxu, 等
出版事項: (2023-07-01)

Advancing pancreatic cancer research and therapeutics: the transformative role of organoid technology
著者:: Jihao Xu, 等
出版事項: (2025-01-01)

Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis
著者:: Qi-An Chen, 等
出版事項: (2024-02-01)

Clinical and Biological Characteristics of Four Patients with Aggressive Systemic Mastocytosis Treated with Midostaurin
著者:: Delia Soare, 等
出版事項: (2025-07-01)

TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT
著者:: Cristina Papayannidis, 等
出版事項: (2022-10-01)

TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT
著者:: Cristina Papayannidis, 等
出版事項: (2022-10-01)

A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin
著者:: Mariarita Sciumè, 等
出版事項: (2021-02-01)

New exploration of KRASG12D inhibitors and the mechanisms of resistance
著者:: Ying Li, 等
出版事項: (2025-03-01)

Adagrasib: A landmark in the KRASG12C‐mutated NSCLC
著者:: He Tian, 等
出版事項: (2022-12-01)

A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer.
著者:: Marta Forés, 等
出版事項: (2017-03-01)

Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia
著者:: Romane Joudinaud, 等
出版事項: (2025-01-01)

Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients
著者:: Mehmet Baysal, 等
出版事項: (2021-03-01)

Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain
著者:: Arenaza A, 等
出版事項: (2019-11-01)

TCR-β Repertoire as a Source of Biomarkers for anti-PD1 Treatment Alone or in Combination With Chemotherapy in Advanced-stage NSCLC Patients
著者:: A. Moreno Manuel, 等
出版事項: (2023-11-01)

Prognostic and Predictive Non-Invasive Biomarkers in Cutaneous Melanoma Treated With Anti PD-1 Antibodies
著者:: S. Torres-Martínez, 等
出版事項: (2023-11-01)

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML
著者:: Mar Tormo, 等
出版事項: (2023-08-01)

Analysis of Immunoregulatory Genes Expression in PBMCs as Potential Predictive and Prognostic Biomarkers in NSCLC Patients Treated with Immunotherapy
著者:: A. Moreno Manuel, 等
出版事項: (2023-11-01)

P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
著者:: Johannes Lübke, 等
出版事項: (2023-08-01)

PB1790: ABCB1 AS A POTENTIAL BENEFICIAL TARGET OF MIDOSTAURIN IN ACUTE MYELOID LEUKEMIA
著者:: S. Sucha, 等
出版事項: (2022-06-01)

Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
著者:: Gabriel Tremblay, 等
出版事項: (2018-10-01)

KRASG12D drives immunosuppression in lung adenocarcinoma through paracrine signaling
著者:: Emily L. Lasse-Opsahl, 等
出版事項: (2025-01-01)

Development of highly potent and selective oncogenic KRASG12D PROTAC degraders
著者:: Yaqiu Mao, 等
出版事項: (2025-12-01)

EGFR controls transcriptional and metabolic rewiring in KRASG12D colorectal cancer
著者:: Dana Krauß, 等
出版事項: (2025-05-01)

Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
著者:: Lisa Goebel, 等
出版事項: (2023-03-01)

Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
著者:: Juan Bautista Blaquier, 等
出版事項: (2021-12-01)

Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations
著者:: Jianxiong Deng, 等
出版事項: (2026-03-01)

Clinical Utility of Liquid Biopsy in the Diagnosis and Monitoring of Patients Affected by PROS Syndromes
著者:: E. Munera-Maravilla, 等
出版事項: (2023-11-01)

Next Generation Sequencing in Liquid Biopsies: Towards Personalized Cancer Treatment.
著者:: S. Gallach Garcia, 等
出版事項: (2023-11-01)

P225 | IMPROVED OUTCOME WITH AVAPRITINIB VS MIDOSTAURIN IN SYSTEMIC MASYOCYTOSIS: A SINGLE-CENTER EXPERIENCE
著者:: M. Fazio, 等
出版事項: (2025-09-01)